Exploratory efficacy analyses in IMpassion130 suggested that PD-L1 expressed on tumor-infiltrating immune cells is the most powerful biomarker for predicting survival benefits of immunotherapeutic regimen for patients with untreated advanced or metastatic TNBC (73). This evidence concerns the gene CD274 and neoplasm.